ACM
GILD icon

Avalon Capital Management’s Gilead Sciences GILD Stock Holding History

Avalon Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,528
Closed -$816K – 95
2017
Q2 		$816K Buy
+11,528
New +$767K 0.6% 53
2016
Q2 		– Sell
-7,430
Closed -$683K – 84
2016
Q1 		$683K Buy
+7,430
New +$670K 0.55% 44

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Avalon Capital Management's GILD Position: Q3 2017 in Review

Avalon Capital Management sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 11,528 shares — an estimated $816K sold.

Avalon Capital Management first reported a position in GILD in Q1 2016 and held it in 2 quarters. The position peaked at $816K in Q2 2017. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Avalon Capital Management reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • Avalon Capital Management sold 11,528 Gilead Sciences shares in Q3 2017, an estimated $816K.
  • Avalon Capital Management first reported a position in Gilead Sciences in Q1 2016 and held it in 2 quarters.
  • Avalon Capital Management's Gilead Sciences position peaked at $816K in Q2 2017.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Avalon Capital Management's 13F filing for Q3 2017, filed 23 Oct 2017.